Earlier this week, Sandoz announced the launch of its adalimumab biosimilar, HYRIMOZ, in 40-mg doses for subcutaneous injection in either a syringe or prefilled pen, in Spain. As we reported earlier, Sandoz previously launched HYRIMOZ in the UK in October 2018. Samsung Bioepsis and Mylan also launched adalimumab biosimilars in…